Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease

Stem Cells

Volumn 30, Issue 4, 2012, Pages 599-611

  Jiang, Yan ^a   Cowley, Sally A ^b   Siler, Ulrich ^c   Melguizo, Dario ^d   Tilgner, Katarzyna ^a   Browne, Cathy ^b   Dewilton, Angus ^b   Przyborski, Stefan ^e   Saretzki, Gabriele ^a   James, William S ^b   Seger, Reinhard A ^c   Reichenbach, Janine ^c   Lako, Majlinda ^a   Armstrong, Lyle ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

^e DURHAM UNIVERSITY   (United Kingdom)

Author keywords

Chronic granulomatous disease; Induced pluripotent stem cells; Macrophages; NADPH

Indexed keywords

GLYCOPROTEIN GP 91; PROTEIN P47; TELOMERASE;

ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL LINE; CHRONIC GRANULOMATOUS DISEASE; CONTROLLED STUDY; EMBRYOID BODY; EMBRYONIC STEM CELL; ENZYME ACTIVITY; GENE MUTATION; GENETIC TRANSDUCTION; GERM LAYER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KARYOTYPE; LENTIVIRINAE; MACROPHAGE; MONOCYTE; NONHUMAN; NUCLEAR REPROGRAMMING; PHAGOCYTE; PLURIPOTENT STEM CELL; SKIN FIBROBLAST; TERATOMA;

CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE; CYTOKINES; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; INDUCED PLURIPOTENT STEM CELLS; KARYOTYPING; KINETICS; MACROPHAGES; MODELS, BIOLOGICAL; MONOCYTES; NADPH OXIDASE; PHENOTYPE; REACTIVE OXYGEN SPECIES;

EID: 84859482750     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1053     Document Type: Article

References (31)

1. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol 2008;140:255-266.
2. Brown JR, Goldblatt D, Buddle J et al. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukoc Biol 2003;73:591-599. (Pubitemid 38040471)
3. Curnutte JT. Chronic granulomatous disease: The solving of a clinical riddle at the molecular level. Clin Immunol Immunopathol 1993;67: S2-S15. (Pubitemid 23195990)
4. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004;4:181-189. (Pubitemid 38339084)
5. Roos D, de Boer M, Kuribayashi F et al. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease. Blood 1996;87:1663-1681. (Pubitemid 26068882)
6. El-Benna J, Dang PM, Perianin A. Peptide-based inhibitors of the phagocyte NADPH oxidase. Biochem Pharmacol 2010;80:778-785.
7. Matute JD, Arias AA, Wright NA et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009;114:3309-3315.
8. Winkelstein JA, Marino MC, Johnston RB, Jr. et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-169. (Pubitemid 30327530)
9. Roesler J, Brenner S, Bukovsky AA, Whiting-Theobald N, Dull T, Kelly M, Civin CI, Malech HL. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. Blood 2002;100:4381-4390. (Pubitemid 35429676)
10. Malech HL, Maples PB, Whiting-Theobald N et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 1997;94: 12133-12138. (Pubitemid 27467855)
11. Malech HHM, Whiting-Theobald N, Linton G et al. Multiple cycles of ex-vivo gene therapy for X-linked chronic granulomatous disease (CGD) sustain production of oxidase-normal peripheral blood neutrophils. Mol Ther 2000;1:S146.
12. Schneider SD, Rusconi S, Seger RA et al. Adenovirus-mediated gene transfer into monocyte-derived macrophages of patients with X-linked chronic granulomatous disease: Ex vivo correction of deficient respiratory burst. Gene Ther 1997;4:524-532. (Pubitemid 27352949)
13. Stein S, Ott MG, Schultze-Strasser S et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16: 198-204.
14. Bianchi M, Hakkim A, Brinkmann V et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009;114: 2619-2622.
15. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131:861-872. (Pubitemid 350138099)
16. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-1920.
17. Woods NB, Parker AS, Moraghebi R et al. Brief report: Efficient generation of hematopoietic precursors and progenitors from human pluripotent stem cell lines. Stem Cells 2011;29:1158-1164.
18. Irion S, Clarke RL, Luche H et al. Temporal specification of blood progenitors from mouse embryonic stem cells and induced pluripotent stem cells. Development 2010;137:2829-2839.
19. Lengerke C, Grauer M, Niebuhr NI et al. Hematopoietic development from human induced pluripotent stem cells. Ann N Y Acad Sci 2009; 1176:219-227.
20. Karlsson KR, Cowley S, Martinez FO et al. Homogeneous monocytes and macrophages from human embryonic stem cells following coculture- free differentiation in M-CSF and IL-3. Exp Hematol 2008;36: 1167-1175.
21. Stojkovic M, Lako M, Stojkovic P et al. Derivation of human embryonic stem cells from day-8 blastocysts recovered after three-step in vitro culture. Stem Cells 2004;22:790-797. (Pubitemid 39166936)
22. Saretzki G, Walter T, Atkinson S et al. Downregulation of multiple stress defense mechanisms during differentiation of human embryonic stem cells. Stem Cells 2008;26:455-464. (Pubitemid 351413606)
23. Gertow K, Przyborski S, Loring JF et al. Isolation of human embryonic stem cell-derived teratomas for the assessment of pluripotency. Curr Protoc Stem Cell Biol 2007; Chapter 1:Unit1B 4.
24. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145-1147. (Pubitemid 28516247)
25. Armstrong L, Saretzki G, Peters H et al. Overexpression of telomerase confers growth advantage, stress resistance, and enhanced differentiation of ESCs toward the hematopoietic lineage. Stem Cells 2005;23:516-529. (Pubitemid 40478491)
26. Cowan CA, Klimanskaya I, McMahon J et al. Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med 2004;350: 1353-1356. (Pubitemid 38375373)
27. Vachier I, Chanez P, Le Doucen C et al. Enhancement of reactive oxygen species formation in stable and unstable asthmatic patients. Eur Respir J 1994;7:1585-1592. (Pubitemid 24294241)
28. Zou J, Sweeney CL, Chou BK et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: Functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011;117:5561-5572.
29. Mishalian I, Ordan M, Peled A et al. Recruited macrophages control dissemination of group a streptococcus from infected soft tissues. J Immunol 2011;187:6022-6031.
30. Leusen JH Verhoeven AJ, Roos D. Interactions between the components of the human NADPH oxidase: Intrigues in the phox family. J Lab Clin Med 1996;128:461-476. (Pubitemid 27506771)
31. Dewald B, Payne TG, Baggiolini M. Activation of NADPH oxidase of human neutrophils. Potentiation of chemotactic peptide by a diacylglycerol. Biochem Biophys Res Commun 1984;125: 367-373. (Pubitemid 15215889)